Related Experiment Video
Updated: Jul 12, 2025
07:15
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
449
Therapeutic Potential Targeting Podocyte Mitochondrial Dysfunction in Focal Segmental Glomerulosclerosis
Yuting Li1,2, Jiaojiao Fan3, Wenping Zhu1,2
1Department of Nephrology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Kidney Diseases (Basel, Switzerland)
|October 30, 2023
Summary
Mitochondrial dysfunction drives podocyte injury and focal segmental glomerulosclerosis (FSGS). Targeting mitochondria with bioactive agents offers promising therapeutic strategies to combat FSGS and slow kidney disease progression.
Area of Science:
- Nephrology
- Cell Biology
- Mitochondrial Medicine
Background:
- Podocytes are crucial for glomerular filtration and maintaining kidney function.
- Podocyte injury is the primary cause of focal segmental glomerulosclerosis (FSGS), leading to proteinuria and nephrotic syndrome.
Purpose of the Study:
- To review recent advances in understanding mitochondrial dysfunction in FSGS.
- To discuss the therapeutic potential of targeting mitochondria for FSGS treatment.
Main Methods:
- Review of current literature on mitochondrial homeostasis and dysfunction in FSGS.
- Analysis of preclinical data on mitochondria-targeted therapeutics.
Main Results:
- Mitochondrial quality control is vital for podocyte health.
- FSGS involves mitochondrial oxidative stress, altered dynamics, and impaired biogenesis.
- Mitochondrial DNA mutations are linked to FSGS.
Conclusions:
- Mitochondrial dysfunction is a key factor in FSGS pathogenesis.
- Therapies targeting mitochondrial health, such as reducing oxidative stress and promoting biogenesis, show promise.
- Targeting the mitochondrial network may offer novel treatment strategies for FSGS and delay progression to end-stage renal disease.
